

March 23, 2015



**Amarantus**  
BioScience

# **Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015**

**- CEO, Gerald E. Commissiong to Present During the Treatments for Alzheimer's and Cognitive Disorders Session on April 7, 2015 From 10:30-11:30 a.m. PDT -**

SAN FRANCISCO and GENEVA, March 23, 2015 (GLOBE NEWSWIRE) --[Amarantus BioSciences Holdings, Inc.](#) (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that Gerald E. Commissiong, President & CEO, will be presenting at the [Neurotech Investing and Partnering Conference](#) being held April 7-8, 2015 at the Hotel Nikko in San Francisco, CA.

Mr. Commissiong will discuss the Company's proprietary Alzheimer's blood diagnostic LymPro Test<sup>®</sup> and the strategic plans for Amarantus Diagnostics on Tuesday, April 7, 2015, from 10:30-11:30 a.m. Pacific Daylight Time during the *Treatments for Alzheimer's and Cognitive Disorders* session focused on the neurodegenerative disorders horizon for symptom improvement, disease modification and the ability for earlier or more accurate diagnosis to improve outcomes.

## **About the Neurotech Investing and Partnering Conference**

Now in its 10th year, the [Neurotech Investing and Partnering Conference](#) is the premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices, software and diagnostics for the brain and nervous system. Organized by the [Neurotechnology Industry Organization](#) and our partner [NeuroInsights](#), the 10th annual conference will be held on Tuesday and Wednesday, April 7-8, 2015 at the Hotel Nikko in San Francisco. The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

## **About LymPro Test<sup>®</sup>**

The Lymphocyte Proliferation Test (LymPro Test<sup>®</sup>) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant

cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.

### **About Amarantus BioScience Holdings, Inc.**

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS has licensed Eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease Levodopa-induced dyskinesia and adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test, (LymPro Test<sup>®</sup>), which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor ("MANF") and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard<sup>™</sup>).

In November 2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns.

On January 12, 2015, AMBS announced the acquisition of DioGenix, Inc., a specialized neuro-diagnostics company, and owns the rights to MSPrecise<sup>®</sup>, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. On January 15, 2015, AMBS executed a one-year exclusive option agreement with Georgetown University to enter into a license for the patent rights related to certain blood based biomarkers for memory loss and Alzheimer's disease jointly owned by Georgetown University and University of Rochester. For further information please visit [www.Amarantus.com](http://www.Amarantus.com), or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

### **Forward-Looking Statements**

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties

should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Investor and Media Contact:

Jenene Thomas

Jenene Thomas Communications, LLC

Investor Relations and Corporate Communications Advisor

T: (US) 908.938.1475

E: [jenene@jenenethomascommunications.com](mailto:jenene@jenenethomascommunications.com)

Source: Amaranthus BioScience Holdings, Inc.